DOACs device market seen reaching $49.48 billion by 2030

The market for direct oral anticoagulants monitoring devices is projected to rise from $32.8 billion in 2025 to $49.48 billion by 2030, driven by growing cardiovascular disease, more atrial fibrillation cases and wider use of point-of-care testing. North America led the market in 2025, according to The Business Research Company.

Why it matters: - Direct oral anticoagulants devices help clinicians measure anticoagulation status in patients taking blood thinners such as rivaroxaban, apixaban, edoxaban and dabigatran. - Better monitoring can help reduce the risk of stroke, blood clots and other complications tied to anticoagulation therapy. - Rising cardiovascular disease rates are increasing demand for tools that support safer, more personalized treatment.

What happened: - The Business Research Company released its Direct Oral Anticoagulants (DOACs) Device Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the market will grow from $32.8 billion in 2025 to $35.69 billion in 2026. - The report projects the market will reach $49.48 billion by 2030. - The report also forecasts a 2025-2030 compound annual growth rate of 8.5%. - North America was the leading region in the DOACs device market in 2025.

The details: - The report points to limited availability of dedicated DOAC monitoring devices as one driver of continued demand. - Hospital-based coagulation testing remains a key part of current monitoring practice. - Growth is linked to the rising prevalence of atrial fibrillation and thrombotic disorders. - Wider adoption of oral anticoagulant therapies is adding to demand. - Patient safety and anticoagulation monitoring remain a major focus across the market. - Future growth is expected to come from portable and point-of-care devices. - Integration with digital health platforms and cloud-based monitoring systems is expected to support adoption. - The report highlights growing acceptance of personalized anticoagulation management. - Homecare and specialty clinic services are expected to expand use cases. - More regulatory approvals for innovative monitoring tools could widen the market. - The report flags increased monitoring of factor Xa and direct thrombin inhibitors as an emerging trend. - Ambulatory and home monitoring options are expanding. - Accuracy, sensitivity and speed of testing remain key product priorities. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report also adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market outlook suggests monitoring is moving beyond hospital settings toward more portable and connected care models. - The growth case appears tied as much to chronic disease burden as to product innovation. - North America's lead suggests the region has the strongest current commercial base for these tools.

What's next: - The report expects point-of-care monitoring, digital integration and home-based testing to play a larger role through 2030. - Regulatory approvals and adoption in specialty and homecare settings could determine how quickly the market scales. - The report provides a free sample and the full market report.